Andrew Hopkins is the Founder and Chief Executive of Exscientia plc, where he has pioneered the use of artificial intelligence and machine learning to design new medicines.

Hopkins led the teams that discovered the first drugs to enter human clinical trials which were designed with the extensive use of machine learning and AI generative methods. For its end-to-end AI-driven precision medicine platform, Exscientia won the Prix Galien USA for Digital Health in 2022 and the Prix Galien UK in the same category in 2023.

Hopkins holds an honorary Professorship at the University of Dundee, where he previously held the Chairs of Medicinal Informatics and Translational Biology. He served as the Director of the Scottish Universities Life Science Alliance and co-founded the European Lead Factory. Prior to the University of Dundee, he spent a decade at Pfizer leading various informatics groups. Hopkins received his DPhil in biophysics from the University of Oxford and LLD from the University of Dundee.